Blood-Based Biomarkers in Alzheimer’s Disease: Advancing Non-Invasive Diagnostics and Prognostics
International Journal of Molecular Sciences · 10.10.2024 · 25 (20) · 10911
DOI: 10.3390/ijms252010911 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.10.2024. Verfasst von Mrinmay Dhauria und 6 weiteren Autor:innen. Beteiligte Einrichtung: Regional Centre for Biotechnology, Faridabad 121001, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Amyloid beta-Peptides. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 209 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, the National Institutes of Health, Bethesda, MD, USA, the Recovery, Transformation, and Resilience Plan at the Ministry of Science and Innovation.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD), the most prevalent form of dementia, is expected to rise dramatically in incidence due to the global population aging. Traditional diagnostic approaches, such as cerebrospinal fluid analysis and positron emission tomography, are expensive and invasive, limiting their routine clinical use. Recent advances in blood-based biomarkers, including amyloid-beta, phosphorylated tau, and neurofilament light, offer promising non-invasive alternatives for early AD detection and disease monitoring. This review synthesizes current research on these blood-based biomarkers, highlighting their potential to track AD pathology and enhance diagnostic accuracy. Furthermore, this review uniquely integrates recent findings on protein-protein interaction networks and microRNA pathways, exploring novel combinations of proteomic, genomic, and epigenomic biomarkers that provide new insights into AD’s molecular mechanisms. Additionally, we discuss the integration of these biomarkers with advanced neuroimaging techniques, emphasizing their potential to revolutionize AD diagnostics. Although large-scale validation is still needed, these biomarkers represent a critical advancement toward more accessible, cost-effective, and early diagnostic tools for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regional Centre for Biotechnology, Faridabad 121001, India.
- Department of Clinical Pharmacology and Therapeutic Medicine, IPGMER and SSKM Hospital, Kolkata 700020, India.
- Department of Stroke Medicine, Institute of Neuroscience, Kolkata 700017, India.
- Department of Biological Sciences, Bose Institute, Kolkata 700054, India.
- Department of Internal Medicine, IPGMER and SSKM Hospital, Kolkata 700020, India.
- Department of Neurology, University Hospital "12 de Octubre", ES-28041 Madrid, Spain.
ORCID-Profile: Mrinmay Dhauria, Ritwick Mondal, Shramana Sarkar, Julián Benito-León
Förderung
- NINDS NIH HHS
- the National Institutes of Health, Bethesda, MD, USA
- the Recovery, Transformation, and Resilience Plan at the Ministry of Science and Innovation
Zitieren
APA
Dhauria, M., Mondal, R., Deb, S., Shome, G., Chowdhury, D., Sarkar, S., & Benito-León, J. (2024). Blood-Based Biomarkers in Alzheimer’s Disease: Advancing Non-Invasive Diagnostics and Prognostics. International Journal of Molecular Sciences, 25(20), 10911. https://doi.org/10.3390/ijms252010911
Vancouver
Dhauria M, Mondal R, Deb S, Shome G, Chowdhury D, Sarkar S, et al. Blood-Based Biomarkers in Alzheimer’s Disease: Advancing Non-Invasive Diagnostics and Prognostics. International Journal of Molecular Sciences. 2024;25(20):10911. doi:10.3390/ijms252010911
BibTeX
@article{Dhauria2024,
author = {Dhauria, Mrinmay and Mondal, Ritwick and Deb, Shramana and Shome, Gourav and Chowdhury, Dipanjan and Sarkar, Shramana and Benito-León, Julián},
title = {Blood-Based Biomarkers in Alzheimer’s Disease: Advancing Non-Invasive Diagnostics and Prognostics},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {20},
pages = {10911},
doi = {10.3390/ijms252010911}
}
EUVIMED